en Pathology Pathology پژوهشي Original Article <p>Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B lymphocytes. It is known as a heterogeneous disease with variable therapeutic responses and alternative therapies. Morphological and immunophenotypical evaluation of the biopsy specimens can help diagnose DLBCL.<br> Methods: In the current study, 44 patients were chosen from Shaheed Sadoghi Hospital (2010&ndash;2013), central Iran. Immunohistochemical method was used for detecting biomarkers such as CD2, CD3, CD20 and CD45.<br> Result: In this study, 54.5% of the patients were men and 45.5% were women. Most of the patients were 40-50 years old. Moreover, 10 (22.7%) patients had lymph node metastasis and 6 (13.6%) patients had stomach involvement. Positive expression of CD45 and CD20 biomarkers were expressed in 100% and 97.7% of the patients. Positive expression of CD3 and CD2 was expressed in 40.9% and 81.8% of the patients, respectively. C-expression of CD45 and CD20 biomarkers was seen in 43 patients. Moreover, there was no relation between biomarkers and sex and age (P>0.05).<br> Conclusion: The result of this study showed that high number of CD45 and CD20 have been seen in Iran&rsquo;s population. Moreover expression of CD20 and CD45 is different as compared with other populations. It seems that these differences can be due to ethnic groups and nature of malignant cells.</p> Diffuse large B cell lymphoma, CD20, CD45, CD3, CD2 68 71 http://ijbc.ir/browse.php?a_code=A-10-256-2&slc_lang=en&sid=1 Robab Sheikhpour r.sheikhpour@yahoo.com 10031947532846003440 10031947532846003440 Yes Fatemeh Pourhosseini 10031947532846003441 10031947532846003441 No